Ras Mitogen-activated Protein Kinase Signaling and Kinase Suppressor of Ras As Therapeutic Targets for Hepatocellular Carcinoma

Overview

Journal J Liver Cancer

Date 2023 Jun 29

PMID 37384270

Authors

Hyuk Moon

Simon Weonsang Ro

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a high incidence cancer and a major health concern worldwide. Among the many molecular signaling pathways that are dysregulated in HCC, the Ras mitogen-activated protein kinase (Ras/Raf/MAPK) signaling pathway has gained renewed attention from basic and clinical researchers. Mutations in Ras and Raf genes which are known to activate the Ras/Raf/MAPK signaling pathway have been infrequently detected in human HCC; however, the Ras/Raf/MAPK signaling pathway is activated in more than 50% of HCC cases, suggesting an alternative mechanism for the activation of the signaling pathway. Kinase suppressor of Ras acts as a molecular scaffold for facilitating the assembly of Ras/Raf/MAPK signaling pathway components and has been implicated in the regulation of this signaling pathway. In this review, we provide important insights into the cellular and molecular mechanisms involved in the activation of the Ras/Raf/MAPK signaling pathway and discuss potential therapeutic strategies for HCC.

Citing Articles

Wogonoside alleviates the proliferation and promotes the apoptosis in liver cancer cells by regulating PI3K/Akt signaling pathway.

Li X, Huang Y, He Y, Ye A Discov Oncol. 2025; 16(1):244.

PMID: 40011302 PMC: 11865406. DOI: 10.1007/s12672-025-01995-5.

Recent Advances in Peptide Inhibitors Targeting Wild-Type Ras Protein Interactions in Cancer Therapy.

Qin W, Liu Z, Huang M, Liang L, Gan Y, Huang Z Int J Mol Sci. 2025; 26(4).

PMID: 40003893 PMC: 11855556. DOI: 10.3390/ijms26041425.

Identification of potential target genes of honokiol in overcoming breast cancer resistance to tamoxifen.

Hermawan A, Putri H, Hanif N, Fatimah N, Prasetio H Front Oncol. 2023; 12:1019025.

PMID: 36601474 PMC: 9806337. DOI: 10.3389/fonc.2022.1019025.

Network-Pharmacology-Based Study on Active Phytochemicals and Molecular Mechanism of in Treating Hepatocellular Carcinoma.

Khan S, Lee T Int J Mol Sci. 2022; 23(10).

PMID: 35628212 PMC: 9140548. DOI: 10.3390/ijms23105400.

References

Taketomi A, Shirabe K, Muto J, Yoshiya S, Motomura T, Mano Y . A rare point mutation in the Ras oncogene in hepatocellular carcinoma. Surg Today. 2012; 43(3):289-92. DOI: 10.1007/s00595-012-0462-8. View

Bruix J, Qin S, Merle P, Granito A, Huang Y, Bodoky G . Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2016; 389(10064):56-66. DOI: 10.1016/S0140-6736(16)32453-9. View

Roy F, Laberge G, Douziech M, Ferland-McCollough D, Therrien M . KSR is a scaffold required for activation of the ERK/MAPK module. Genes Dev. 2002; 16(4):427-38. PMC: 155344. DOI: 10.1101/gad.962902. View

Hoffmann K, Shibo L, Xiao Z, Longerich T, Buchler M, Schemmer P . Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma. Anticancer Res. 2011; 31(11):3883-90. View

Rajalingam K, Schreck R, Rapp U, Albert S . Ras oncogenes and their downstream targets. Biochim Biophys Acta. 2007; 1773(8):1177-95. DOI: 10.1016/j.bbamcr.2007.01.012. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Ory S, Zhou M, Conrads T, Veenstra T, Morrison D . Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr Biol. 2003; 13(16):1356-64. DOI: 10.1016/s0960-9822(03)00535-9. View

Zhang H, Zhu Y, Qin X, Wang C, Yao X, Zhang S . c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature. Clin Genitourin Cancer. 2012; 11(2):134-40. DOI: 10.1016/j.clgc.2012.08.007. View

Therrien M, Chang H, Solomon N, Karim F, Wassarman D, Rubin G . KSR, a novel protein kinase required for RAS signal transduction. Cell. 1995; 83(6):879-88. DOI: 10.1016/0092-8674(95)90204-x. View

10.

Razidlo G, Kortum R, Haferbier J, Lewis R . Phosphorylation regulates KSR1 stability, ERK activation, and cell proliferation. J Biol Chem. 2004; 279(46):47808-14. DOI: 10.1074/jbc.M406395200. View

11.

Michaud N, Therrien M, Cacace A, Edsall L, Spiegel S, Rubin G . KSR stimulates Raf-1 activity in a kinase-independent manner. Proc Natl Acad Sci U S A. 1997; 94(24):12792-6. PMC: 24217. DOI: 10.1073/pnas.94.24.12792. View

12.

Jindal A, Thadi A, Shailubhai K . Hepatocellular Carcinoma: Etiology and Current and Future Drugs. J Clin Exp Hepatol. 2019; 9(2):221-232. PMC: 6477125. DOI: 10.1016/j.jceh.2019.01.004. View

13.

Brennan D, Dar A, Hertz N, Chao W, Burlingame A, Shokat K . A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature. 2011; 472(7343):366-9. DOI: 10.1038/nature09860. View

14.

Weinstein I . Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-4. DOI: 10.1126/science.1073096. View

15.

Zhang J, Zafrullah M, Yang X, Yin X, Zhang Z, Fuks Z . Downregulation of KSR1 in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake. Cancer Biol Ther. 2008; 7(9):1490-5. PMC: 2576298. DOI: 10.4161/cbt.7.9.6472. View

16.

Koral K, Paranjpe S, Bowen W, Mars W, Luo J, Michalopoulos G . Leukocyte-specific protein 1: a novel regulator of hepatocellular proliferation and migration deleted in human hepatocellular carcinoma. Hepatology. 2014; 61(2):537-47. PMC: 4303494. DOI: 10.1002/hep.27444. View

17.

Tan X, Egami H, Abe M, Nozawa F, Hirota M, Ogawa M . Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway. J Clin Pathol. 2005; 58(12):1242-8. PMC: 1770786. DOI: 10.1136/jcp.2004.025338. View

18.

Harada N, Oshima H, Katoh M, Tamai Y, Oshima M, Taketo M . Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res. 2004; 64(1):48-54. DOI: 10.1158/0008-5472.can-03-2123. View

19.

Calvisi D, Ladu S, Gorden A, Farina M, Conner E, Lee J . Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006; 130(4):1117-28. DOI: 10.1053/j.gastro.2006.01.006. View

20.

Gysin S, Lee S, Dean N, McMahon M . Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Res. 2005; 65(11):4870-80. DOI: 10.1158/0008-5472.CAN-04-2848. View